FHLC vs IHI

Key Takeaways

• FHLC offers broad exposure to the U.S. healthcare sector with approximately 340 holdings, while IHI provides concentrated exposure to medical devices with around 47 holdings.
• FHLC's expense ratio of 0.08% is significantly lower than IHI's 0.38%, enhancing cost efficiency for long-term investors.
• Top holdings in FHLC include pharmaceuticals like LLY (11.26%) and JNJ (9.02%), contrasting with IHI's device-focused leaders such as ISRG (16.53%) and ABT (16.06%).
• FHLC diversifies across pharmaceuticals, biotechnology, equipment, and services; IHI is 100% medical devices, leading to higher concentration risk.
• Both ETFs are passive and non-diversified, tracking market-cap-weighted indexes with FHLC including small-caps for broader coverage.
• IHI exhibits higher liquidity with greater average daily volume, appealing for tactical trading.

Introduction

Healthcare remains a cornerstone of defensive investing amid economic uncertainty and sector rotation in recent market cycles. FHLC and IHI offer distinct paths within this resilient sector: FHLC delivers comprehensive U.S. healthcare exposure, capturing pharmaceuticals, biotech, providers, and devices, while IHI targets the specialized medical devices subsector. Investors compare them for diversification versus thematic purity, especially as innovation in devices and drug pipelines drives growth amid aging demographics and regulatory shifts. This analysis highlights structural differences to inform allocation decisions in the current environment.

Fidelity MSCI Health Care Index ETF (FHLC) Overview

The Fidelity MSCI Health Care Index ETF (FHLC) is a passive ETF that tracks the MSCI USA IMI Health Care 25/50 Index, representing the broad U.S. healthcare equity market across large-, mid-, and small-cap companies. It holds approximately 340 securities, providing extensive diversification. Top holdings include LLY (11.26%), JNJ (9.02%), ABBV (5.93%), UNH (5.53%), and MRK (4.53%), with the top 10 comprising about 50% of assets.

Sector allocations emphasize health technology (around 80%), including pharmaceuticals and biotechnology, health services (13%), and equipment/supplies. The expense ratio is a low 0.08%, and assets under management (AUM) stand at roughly $2.85 billion. As a non-diversified fund, it invests at least 80% in index securities, with low turnover reflecting quarterly rebalancing typical of MSCI indexes.

iShares U.S. Medical Devices ETF (IHI) Overview

The iShares U.S. Medical Devices ETF (IHI) passively tracks the Dow Jones U.S. Select Medical Equipment Index, focusing on U.S. companies manufacturing and distributing non-disposable medical devices like scanners and pacemakers. It maintains about 47 holdings, resulting in higher concentration. Top holdings feature ISRG (16.53%), ABT (16.06%), SYK (11.04%), EW (4.98%), and IDXX (4.74%), with the top 10 accounting for over 75% of assets.

Sector allocation is 100% healthcare, specifically medical equipment. The expense ratio is 0.38%, with AUM around $3 billion and strong liquidity via average daily volume exceeding 2 million shares. Non-diversified and market-cap-weighted, it rebalances periodically to reflect index methodology.

Industry and Thematic Backdrop

The U.S. healthcare sector benefits from structural tailwinds like an aging population, rising chronic disease prevalence, and technological innovation, positioning it as a defensive growth area. Recent capital flows have favored broad healthcare amid market rotations away from tech, with ETFs seeing inflows after years of underperformance. Catalysts include advancements in GLP-1 drugs, AI-driven diagnostics, and medical devices for minimally invasive procedures. Regulatory developments, such as drug pricing reforms, pose risks to pharmaceuticals but less so to devices. Macro drivers like moderating interest rates support capital-intensive biotech and equipment firms, while geopolitical stability aids supply chains. Sector risks encompass policy changes and reimbursement pressures, yet healthcare's essential nature ensures resilience across cycles.

Performance and Positioning Comparison

In recent months, broad healthcare ETFs like FHLC have shown relative stability, buoyed by diversified exposure to steady earners in pharmaceuticals and services amid sector rotation. FHLC's inclusion of small-caps adds volatility but captures upside from biotech rallies. Conversely, IHI has experienced sharper swings, underperforming in periods of device sector weakness due to high concentration in growth-oriented holdings like ISRG, yet outperforming during innovation-driven cycles tied to procedural volumes and elective surgeries rebounding post-pandemic.

FHLC's lower beta (around 0.64) reflects smoother positioning versus IHI's higher beta (0.94), linking to broader macro shifts like interest rate expectations favoring value-oriented providers over high-growth devices. Volatility differences stem from FHLC's diversification mitigating subsector downturns, while IHI amplifies equipment trends amid earnings cycles and commodity influences on manufacturing.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization (market cap), technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions across asset classes. Explore it today to enhance your ETF comparison and strategy development.

Tickeron AI Verdict

Tickeron’s AI currently favors FHLC due to its superior cost efficiency, broader diversification across healthcare subsectors, and consistent trend alignment in recent market cycles. While IHI offers targeted exposure to high-growth medical devices with strong liquidity, its concentration elevates risk amid subsector volatility. FHLC's structural advantages position it probabilistically better for sustained sector momentum, though IHI may appeal in device-specific uptrends.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations